AFTER MORE THAN 40 YEARS OF NMIBC TREATMENT, LITTLE HAS EVOLVED BUT OUR DESIRE TO DO MORE1

Although significant progress has been made in treating many tumor types, outcomes for patients with NMIBC (non–muscle-invasive bladder cancer) have remained stagnant for decades.1 It’s time to look closely at where we stand with bladder cancer.

READ ABOUT THE TREATMENT EXPERIENCES FOR
THESE PATIENTS WITH BLADDER CANCER
Rick, Age 51 Currently undergoing BCG, Not an actual patient
Rick, age 51
Currently undergoing BCG

I'm currently undergoing BCG treatments. I'm glad I have this option before thinking about cystectomy, but there are challenges.

William, Age 72, BCG treatment interrupted, Not an actual patient
William, age 72
BCG Treatment Interrupted

I wasn’t always able to get my BCG treatment or I would get less than I was supposed to because of shortages. I worry that my cancer will get worse.

Michelle, Age 44, BCG-unresponsive, Not an actual patient
Michelle, age 44
BCG-Unresponsive

My cancer recurred after completing all of my BCG treatments. Now my urologist is recommending cystectomy, but I'm struggling with this decision.

BCG=Bacillus Calmette–Guérin.
Reference:

  1. Cancer stat facts: bladder cancer. National Cancer Institute: Surveillance, Epidemiology, and End Results Program. Accessed February 13, 2024. https://seer.cancer.gov/statfacts/html/urinb.html